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Validation of a contemporary prostate cancer
grading system using prostate cancer death
as outcome
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Background: Gleason scoring (GS) has major deficiencies and a novel system of five grade groups (GSp6; 3þ 4; 4þ 3; 8;X9) has
been recently agreed and included in the WHO 2016 classification. Although verified in radical prostatectomies using PSA relapse
for outcome, it has not been validated using prostate cancer death as an outcome in biopsy series. There is debate whether an
‘overall’ or ‘worst’ GS in biopsies series should be used.
Methods: Nine hundred and eighty-eight prostate cancer biopsy cases were identified between 1990 and 2003, and treated
conservatively. Diagnosis and grade was assigned to each core as well as an overall grade. Follow-up for prostate cancer death
was until 31 December 2012. A log-rank test assessed univariable differences between the five grade groups based on overall and
worst grade seen, and using univariable and multivariable Cox proportional hazards. Regression was used to quantify differences
in outcome.
Results: Using both ‘worst’ and ‘overall’ GS yielded highly significant results on univariate and multivariate analysis with overall GS
slightly but insignificantly outperforming worst GS. There was a strong correlation with the five grade groups and prostate cancer
death.
Conclusions: This is the largest conservatively treated prostate cancer cohort with long-term follow-up and contemporary
assessment of grade. It validates the formation of five grade groups and suggests that the ‘worst’ grade is a valid prognostic
measure.
The Gleason grading of prostate cancer has been established for
over 40 years (Gleason, 1966). Although the basic grading
categories have remained unchanged in this time, there have been
numerous changes in the methodologies used to determine the
Gleason score (GS) of prostate cancer over that period.
Changes were first introduced in the 1970s (Gleason and
Melliger, 1974). The advent of immunochemistry for basal cell
markers in the 1990s introduced further upward shifts in Gleason
grading as it was realised that many low-grade lesions diagnosed as
prostate cancer were benign lesions such as atypical adenomatous
hyperplasia (Bostwick and Chang, 1999; Berney et al, 2007).
A number of authors cautioned on the diagnosis of very low GSs
(Epstein, 2000; Berney, 2007), and this was codified in the 2005
consensus meeting of the International Society of Urological
Pathology (ISUP) 2005 (Epstein et al, 2005), where it was
recommended that scores o6 ‘should rarely if ever’ be made.
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More recently, at the 2014 ISUP Chicago conference it was agreed
that GSs 2–4 ‘should not be made’ on biopsy (Epstein et al, 2016).
Although no statements were made concerning GS 5 (3þ 2 or
2þ 3), this score is currently also rarely assigned on biopsy.
There have been further debates since then on unresolved issues
on Gleason grading. It has been shown in numerous studies that
GS 3þ 3¼ 6 tumours show little propensity to recur or
metastasise, when completely resected by radical prostatectomy
(Miyamoto et al, 2009; Ross et al, 2012). However, as biopsy
specimens remain samples of the tumour, there remains a degree
of uncertainty on whether there is un-sampled higher-grade
tumour present whenever GS 3þ 3¼ 6 is diagnosed.
GS ranges from 2 to 10, but the fact that 6 is the lowest
practicable score is very confusing for clinicians and patients
(Berney, 2007).
A further concern is that GS 3þ 4¼ 7 and GS 4þ 3¼ 7 are not
separated in most current prognostic tools, although many studies
have shown the differences in these scores to be prognostically
significant.
In an era when active surveillance is increasingly offered to
patients with low-risk prostate cancer, a revision to prostate cancer
grading has been proposed (Pierorazio et al, 2013) based on five
grade groups. This has been accepted by a meeting of senior
uropathologists, oncologists and surgeons at an ISUP conference in
Chicago in 2014 (Epstein et al, 2016). The correlation of GS and
grade groups is shown in Table 1.
This grading system has been validated using biochemical
relapse as an outcome in a large international series of radical
prostatectomy patients (Epstein et al, 2015). However, it has not
been validated in a conservatively treated cohort, with prostate
cancer death at the end point.
There are other crucial refinements in the interpretation of
prostate cancer grading, which need to be clarified for use by
clinicians and pathologists. There have been some changes to the
pattern assignments seen. Cribriform glands and glomeruloid
glands, it has been agreed, should all be given a Gleason pattern of
four in line with a number of separate lines of evidence on
cribriform (Martinez-Rodriguez et al, 2007; Dong et al, 2013; Kir
et al, 2014; Kweldam et al, 2014; van der Kwast, 2014) and
glomeruloid patterns (Pacelli et al, 1998; Gobbi et al, 1999; Lotan
and Epstein, 2009; Liu, Chang et al, 2011). There has been debate
on whether the ‘worst’ score seen in a single core of a biopsy series
is more or less predictive of outcome than an ‘overall’ score judged
by the pathologist after reviewing the whole series (Kunz and
Epstein, 2003; Kunju et al, 2009; Tolonen et al, 2011). Both ‘worst’
or ‘overall’ score are used throughout Europe in pathology practice
(Berney et al, 2013), although typically the highest score is used by
clinicians (Rubin et al, 2004).
In this study, we examine the proposed changes in the grading
of prostate cancer in a biopsy series treated conservatively and re-
reviewed to these new standards. We investigate whether this new
grading system can be applied to this data set and whether ‘overall’
or ‘worst’ score best predicts prostate cancer death.
MATERIALS AND METHODS
Patients. Cases of prostate cancer were identified from three
cancer registries in Great Britain. Within each region, collaborating
hospitals were sought and cases from these hospitals were
reviewed. Men were included in this study if they were under
age 76 years at the date of diagnosis and had clinically localised
prostate cancer diagnosed by needle biopsy between 1990 and 2003
inclusively. The median date of diagnosis was May 2002. Patients
treated by radical prostatectomy or radiation therapy within 6
months of diagnosis were excluded. In addition, those with
objective evidence of metastatic disease (by bone scan, X-ray,
radiograph, CT scan, MRI, bone biopsy, lymph node biopsy and
pelvic lymph node dissection) or clinical indications of metastatic
disease (including pathologic fracture, soft-tissue metastases, spinal
compression, or bone pain), or a PSA measurement over
100 ngml 1 at or within 6 months of diagnosis were also
excluded. Men who had hormone therapy before the diagnostic
biopsy were also excluded, because of the influence of hormone
treatment on Gleason pattern. We also excluded men who died
within 6 months of diagnosis, or had o6 months of follow-up.
Original histological specimens from the diagnostic procedure
were requested and centrally reviewed by a panel of three expert
urological pathologists to confirm the diagnosis of adenocarcinoma
and to reassign GSs using of a contemporary and consistent
interpretation of the Gleason scoring system (Epstein, 2010). The
panel met and discussed all controversial cases and a selection of
others to audit the data set. Cribriform and glomeruloid glands
were all assigned a Gleason pattern 4. All the cores in each case
were given a separate score, and an overall score for the case was
also given based on the opinion of the pathologist for each case.
Overall grading was assigned by the opinion of the pathologist and
the methodology agreed in consensus before analysis. The method
chosen was to assign an overall grade thought to be the best
estimate of what would be seen at radical prostatectomy. For
instance, in a biopsy series with numerous cores with Gleason
4þ 3¼ 7 and a small amount of Gleason 4þ 4¼ 8 or even higher
in a single core, the pathologist might judge that Gleason 4þ 3¼ 7
was a more representative score. It was also taken into account that
tiny amounts of pattern 5 carcinoma are not included in the
grading of radical prostatectomy specimens but given a tertiary
score. Percentages of each pattern seen were given. Follow-up was
conducted through the cancer registries and the cut-off date was 31
December 2012. Deaths were divided into those from prostate
cancer and those from other causes, according to World Health
Organisation standardised criteria (WHO, 2010). National ethics
approval was obtained from the Northern Multicentre Research
Ethics Committee, followed by local ethics committee approval at
each of the collaborating hospitals.
Statistical analysis. Survival was analysed with a Cox proportional
hazards model. The primary end point was death from prostate
cancer. Observations were censored on the date of last follow-up,
or at death from other causes. All events were used for estimating
hazard ratios (maximum follow-up 232 months), but follow-up
was censored at 10 years for predicting 10-year risks. Covariates
evaluated were: centrally reviewed overall and worst GS, baseline
PSA value, clinical stage, extent of disease (proportion of positive
cores), age at diagnosis and use of hormone treatment. Analysis
Table 1. A detailed comparison of contemporary Gleason
scoring and grade groups
Comparison of Gleason grading and Grade groups
GSp6 Grade group 1
GS 3þ 4¼ 7 Grade group 2
GS 4þ 3¼ 7 (if % grade 3X5%) Grade group 3
GS 4þ 4¼ 8 Grade group 4
GS 4þ 3¼ 7 (if o5% pattern 3)
GS 3þ 5¼ 8
GS 5þ 3¼ 8
GS 4þ 5¼ 9 Grade group 5
GS 5þ 4¼ 9
GS 5þ 5¼ 10
Abbreviation: GS¼Gleason score.
BRITISH JOURNAL OF CANCER Validation of new prostate cancer grading
2 www.bjcancer.com |DOI:10.1038/bjc.2016.86
was repeated substituting ‘worst’ GS for ‘overall’ GS and analysed
according to the five grade groups.
Baseline PSA concentration was defined as the last pre-
diagnostic PSA measurement within 6 months before diagnosis.
If no such PSA value was available, we took the first post-
diagnostic PSA within 6 months; failing that, the pre-diagnostic
PSA taken closest to the date of diagnosis was used. All PSA values
after treatment with hormones or orchiectomy or within 3 weeks
after a surgical procedure to the prostate were excluded.
PSA concentration was modelled as the natural logarithm of
(1þPSA (ngml 1)). Patients with values 4100 ngml 1 were
excluded as likely to be metastatic disease. GSs were evaluated in
five prognostic grade categories by ‘worst’ GS and ‘overall’ GS.
The primary assessment was a univariate analysis of the
association between grade group by overall GS and death from
prostate cancer and repeated for ‘worst’ GS. Statistical analyses
were done with STATA (version 12, StataCorp, College Station,
TX, USA) and R (version 3.0, The R Foundation for Statistical
Computing, Vienna, Austria). Multivariate analysis included
clinical T stage, diagnostic serum PSA and the volume of disease
(percentage of involved cores), and method of treatment (initial
hormone treatment or no initial hormonal treatment).
RESULTS
Six thousand five-hundred and one cores from 988 individual cases
were assessed for malignancy and graded. The mean, median and
interquartile range of patient age, number of cores sampled, serum
PSA and percentage of cores involved is shown in Table 2. Cases
were divided into the 5 prognostic grade groups from the GS and a
comparison between the prognostic grade groups using both
‘worst’ and ‘overall’ GS is seen in Figure 1.
Both ‘overall’ and ‘worst’ GS analysis yielded highly significant
results. The significance of log rank for overall GS in five grade
groups was P¼ 2.79 10 26 (w2¼ 126 df¼ 4). For the worst GS
this was P¼ 1.43 10 24 (118 w2 df¼ 4) with overall GS,
therefore, slightly but insignificantly outperforming worst GS. It
should be noted that GS 3þ 4¼ 7 (grade group 2) separated highly
significantly from GS 4þ 3¼ 7 (grade group 3). Cox model
analysis with hazard ratios by both overall and worst grade group
seen also showed high levels of significance (Table 3 and Figure 2).
Out of 988 patients, 574 received early hormonal therapy,
whereas 414 received watchful waiting only as initial treatment.
When analysed separately using overall assessments of grade
group for the early hormone-treated group, P¼ 2.85 10 12
(w2¼ 60 df¼ 4), whereas for the non-hormone-treated group,
P¼ 1.05 10 5 (w2¼ 23.4 df¼ 4).
On multivariate analysis in comparison with log PSA, extent of
disease (percentage of involved cores),T stage (stages 3 and 4
merged) and including the method of initial treatment, grade
group remained significant with a w2 (4df) of 10.3 for overall grade
and 9.2 for worst grade. (Table 4), A complete data set was
available on 755 patients, with some patients missing details of
clinical stage. For the multivariate Cox models, the Harrell
c-statistic for overall grade is 0.756 (se¼ 0.028) and for worst
grade is 0.752 (se¼ 0.028).
Removal of extent of disease from the multivariate model,
(which was of low significance) resulted in in an increase in log
PSA significance with a higher hazard ratio (1.36) and more
significant P-value (0.010) and on tumour stage 3/4 vs 1 with a
higher hazard ratio (2.30) and more significant P-value (0.010)
with similar changes in the worst grade multivariate model; (log
PSA hazard ratio¼ 1.37, P¼ 0.008) and (tumour stage hazard
ratio¼ 2.46, P¼ 0.010).
DISCUSSION
These results show, for the first time, that in a conservatively
treated cohort with prostate cancer death as an outcome,
interpretation of GS using modern criteria can effectively separate
Table 2. Distribution of the mean, median and interquartile range of patient age, serum PSA, number of cores sampled and













Age (mean (s.d.)) 69.6 (5.0) 68.7 (5.4) 69.6 (5.2) 70.3 (4.3) 71.3 (3.4) 69.9 (5.1)
PSA (median (Q1–Q3)) 14.2 (8.1–31.0) 8.8 (6.9–13.6) 15.0 (8.6–27.2) 22.9 (11.0–48.5) 19.4 (9.5–48.8) 31.0 (15.9–52.6)
#Cores (median (Q1–Q3)) 6 (5–8) 6 (6–8) 6 (5–8) 6 (4–7) 6 (4–8) 6 (4–7)
Tumour % (median (Q1–Q3)) 22.0 (7.3–53.4) 6.1 (2.7–12.5) 27.3 (11.5–50.9) 42.4 (18.1–71.4) 33.1 (6.1–68.1) 66.8 (39.9–93.9)









Grade group 1 Grade group 2 Grade group 3 Grade group 4 Grade group 5
Overall score Worst score
Figure 1. Comparison of overall and worst Grade Group frequencies.
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five prognostic grade groups. The power of grade groups to predict
outcome in this cohort is considerable. It shows that modern
interpretation of GS is not only valid using pathological surrogates
for outcome or biochemical recurrence but indicates that it
correlates with prostate cancer death. We also suggest that grade
groups, as suggested in other papers, can be confidently used in
reports alongside GS. This will aid both clinicians and patients in
their understanding of the severity of the cancer and aid treatment
decisions and counselling for active surveillance patients. Gleason
scoring presents a ‘skewed’ scale to patients, with a scale running
from 2 to 10, when the lowest valid score is 6. Explaining to
patients that a GS 6 cancer is low risk can be difficult. Translation
of this to ‘grade group 1’ will be easier for patients to understand,
and for clinicians to explain (Berney, 2007).
It should be especially noted that there is a significant split
between GS 3þ 4¼ 7 and GS 4þ 3¼ 7, (grade groups 2 and 3),
which has not been well translated in previous risk assessments
such as CAPRA (May et al, 2007; Lughezzani et al, 2010).
The least significant separation is between GC 4þ 3¼ 7 and
4þ 4¼ 8, and requires further investigation. Certainly, minor
elements of pattern 3 cancer seem to matter little in overall
prognosis.
The use of an ‘overall’ or ‘worst’ score has been considerably
debated in the literature (Kunju et al, 2009; Tolonen et al, 2011).
There is great variability in how GS is assigned in different centres.
Some have advocated assigning a GS to every core and giving no
‘overall’ score for the case. Other pathologists give a GS per
submitted specimen pot: which might include more than one
core (Berney et al, 2013). There have been no direct comparisons
of the different methods in a series of conservatively treated
prostate carcinomas with long-term outcome. There is a concern
that a ‘worst’ GS might overstate the severity of the disease,
especially when the volume of high-grade disease in a single
core is small and there is widespread disease of a lower grade in
other cores.
We have shown here that the ‘worst’ GS has a very similar
prognostic ability to an ‘overall’ GS. As it is easier to calculate and
relies less on the subjectivity of individual consultant pathologists
we advocate its use in routine practice. Using the ‘worst’ GS, there
appears to be greater separation of grade groups 3 and 4. Also the
‘worst’ GS was used in both the initial and validating studies of
grade groups which showed significant differences between grade
groups 3 and 4 (Pierorazio et al, 2013; Epstein et al, 2015). Also,
the ‘rules’ for assigning an overall GS are not clear, and prone to
variation between pathologists.
The strengths of this study include the large sample size and
detailed nature of the centralised pathological review. In many
series it is unclear whether individual cores have been separately
graded, especially when they are processed within one cassette
or slide.
The weaknesses of the study include its retrospective nature, and
the criticism that prostate cancer is no longer treated in the same
manner as it was 20 years ago. The majority of the cohort is from
sextant biopsies, which is not contemporary practice. This is an
unavoidable weakness of current retrospective studies to allow
sufficient follow-up to look at prostate cancer death as an outcome.
This is a problem for all current long-term studies of prostate
cancer outcome, and can also be levelled at large trials such
as PROTECT (Oxley et al, 2015), where the methods of biopsy are
not now standard of care. This will be an on-going problem in
prostate cancer outcome studies, with the continuing advance of
imaging and template biopsy techniques. For the foreseeable
future, pathological grading of prostate cancer will remain standard
of care, and adjuvant techniques such as imaging or molecular
Table 3. Cox Model analysis with hazard ratios by overall and
worst grade groups–estimates compared with reference







1 307 (15) 1 (ref)
2 303 (39) 2.81 (1.55, 5.10) 0.00067
3 210 (52) 6.05 (3.40, 10.76) 9.5 1010
4 56 (15) 7.12 (3.48, 14.6) 7.8108
5 112 (48) 12.67 (7.09, 22.64) o21016
Overall w2¼ 110.1, P-value¼6.9 10 23.
Grade group (worst)
1 307 (15) 1 (ref)
2 244 (31) 2.69 (1.45, 4.98) 0.0017
3 206 (46) 5.29 (2.94, 9.49) 2.5108
4 111 (28) 6.88 (3.67, 12.9) 1.7109
5 120 (49) 12.0 (6.72, 21.4) o21016
Overall w2¼ 105.9, P-value¼5.4 10 22.
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Figure 2. Kaplan–Meier plots of the 5 Grade Groups by worst Grade
Group (A) and overall Grade Group (B).
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pathology which are complementary are unlikely to take over from
the current gold standard.
In conclusion, we have validated five grade groups in a biopsy
series of prostate cancer using prostate cancer death as an outcome.
This study compliments other studies using PSA relapse as an
outcome for the use of this system internationally.
ACKNOWLEDGEMENTS
We gratefully acknowledge support from Cancer Research UK,
ORCHID, a SPORE grant from the US National Cancer Institute
(P50CA09629), the David H. Koch Fund and Myriad Genetics. We
thank investigators and staff in the cancer registries and
participating hospitals for their support.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Berney DM (2007) The case for modifying the Gleason grading system. BJU
Int 100(4): 725–726.
Berney DM (2007) Low Gleason score prostatic adenocarcinomas are no
longer viable entities. Histopathology 50(6): 683–690.
Berney DM, Algaba F, Camparo P, Comperat E, Griffiths D, Kristiansen G,
Lopez-Beltran A, Montironi R, Varma M, Egevad L (2013) The reasons
behind variation in Gleason grading of prostatic biopsies: areas of
agreement and misconception among 266 European pathologists.
Histopathology 64(3): 405–411.
Berney DM, Fisher G, Kattan MW, Oliver RT, Moller H, Fearn P, Eastham J,
Scardino P, Cuzick J, Reuter VE, Foster CS (2007) Pitfalls in the diagnosis
of prostatic cancer: retrospective review of 1791 cases with clinical
outcome. Histopathology 51(4): 452–457.
Bostwick DG, Chang L (1999) Overdiagnosis of prostatic adenocarcinoma.
Semin Urol Oncol 17(4): 199–205.
Dong F, Yang P, Wang C, Wu S, Xiao Y, McDougal WS, Young RH, Wu CL
(2013) Architectural heterogeneity and cribriform pattern predict adverse
clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg
Pathol 37(12): 1855–1861.
Epstein JI (2000) Gleason score 2-4 adenocarcinoma of the prostate on
needle biopsy: a diagnosis that should not be made. Am J Surg Pathol
24(4): 477–478.
Epstein JI (2010) An update of the Gleason grading system. J Urol 183(2):
433–440.
Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL (2005) The 2005
International Society of Urological Pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma. Am J Surg Pathol
29(9): 1228–1242.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA,
Grading C (2016) The 2014 International Society of Urological Pathology
(ISUP) consensus conference on gleason grading of prostatic carcinoma:
definition of grading patterns and proposal for a new grading system.
Am J Surg Pathol 40(2): 244–252.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C,
Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P,
Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA (2015) A contemporary
prostate cancer grading system: a validated alternative to the gleason score.
Eur Urol 69(3): 428–435.
Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother
Rep 50: 125–128.
Table 4. Multivariate analysis of overall and worst grade group including stage, PSA, initial treatment method and extent of
disease. (% disease expressed as % of involved biopsy cores)
Variable No. of Men (deaths) Hazard ratio (95% CI) v2 (df) P-Value
Grade group (overall grade) 9.72 (4) 0.046
1 237 (12) 1 (ref)
2 237 (32) 1.81 (0.90, 3.66) 0.099
3 159 (41) 2.63 (1.26, 5.47) 0.010
4 43 (9) 2.51 (0.99, 6.28) 0.050
5 79 (28) 3.17 (1.41, 7.12) 0.005
Log PSA 1.21 (0.95–1.55) 3.7 (1) 0.122
T stage 10.9 (2) 0.004
T stage 1 135 (15) 1 (ref)
T stage 2 475 (53) 1.04 (0.57, 1.91) 0.894
T stage 3/4 145 (54) 2.11 (1.08, 4.12) 0.028
% disease (per 10%) 1.66 (1) 0.202
Hormones¼n 301 (23) 1.05 (0.97, 1.14), 1 (ref) 2.85 (1) 0.100
Hormones¼ y 454 (99) 1.54 (0.92–2.59)
Grade group (worst grade) 7.5 (4) 0.110
1 237 (12) 1 (ref)
2 184 (25) 1.89 (0.92, 3.89) 0.083
3 155 (36) 2.17 (1.03, 4.58) 0.042
4 92 (20) 2.60 (1.19, 5.68) 0.017
5 87 (29) 2.79 (1.24, 6.27) 0.013
Log PSA 1.21 (0.95–1.55) 2.5 (1) 0.121
T stage 12.1 0.0024
T stage 1 135 (15) 1 (ref)
T stage 2 475 (53) 1.03 (0.56, 1.90) 0.946
T stage 3/4 145 (54) 2.19 (1.12, 4.26) 0.024
% Disease (per 10%) 2.05 0.153
Hormones¼n 301 (23) 1.06 (0.98,1.11), 1 (ref) 3.14 (1) 0.077
Hormones¼ y 454 (99) 1.58 (0.94–2.65)
Abbreviations: CI¼ confidence interval; df¼degrees of freedom; PSA= prostatic specific antigen.
Validation of new prostate cancer grading BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.86 5
Gleason DF, Melliger GT (1974) Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging.
J Urol 11: 7.
Gobbi H, Simpson JF, Jensen RA, Coogan AC, Page DL (1999) Prostatic
adenocarcinoma with glomeruloid features. Hum Pathol 30(1): 111–112.
Kir G, Sarbay BC, Gumus E, Topal CS (2014) The association of the
cribriform pattern with outcome for prostatic adenocarcinomas.
Pathol Res Pract 210(10): 640–644.
Kunju LP, Daignault S, Wei JT, Shah RB (2009) Multiple prostate cancer cores
with different Gleason grades submitted in the same specimen container
without specific site designation: should each core be assigned an
individual Gleason score? Hum Pathol 40(4): 558–564.
Kunz Jr GM, Epstein JI (2003) Should each core with prostate cancer be
assigned a separate gleason score? Hum Pathol 34(9): 911–914.
Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH,
van Leenders GJ (2014) Cribriform growth is highly predictive for
postoperative metastasis and disease-specific death in Gleason score 7
prostate cancer. Mod Pathol 28(3): 457–464.
Liu Z, Chang B, Guo SM, Wang T, Li MC, Yang J, Chen K, Yang WM, Liu JH,
Ye ZQ (2011) Prostatic adenocarcinoma with glomeruloid structure.
Beijing Da Xue Xue Bao 43(4): 519–521.
Lotan TL, Epstein JI (2009) Gleason grading of prostatic adenocarcinoma
with glomeruloid features on needle biopsy. Hum Pathol 40(4):
471–477.
Lughezzani G, Budaus L, Isbarn H, Sun M, Perrotte P, Haese A, Chun FK,
Schlomm T, Steuber T, Heinzer H, Huland H, Montorsi F, Graefen M,
Karakiewicz PI (2010) Head-to-head comparison of the three most
commonly used preoperative models for prediction of biochemical
recurrence after radical prostatectomy. Eur Urol 57(4): 562–568.
Martinez-Rodriguez M, Ramos D, Mayordomo E, Soriano P, Llombart-Bosch A
(2007) Analysis of cribriform Gleason grade 3 in prostatic carcinoma.
A histopathological and immunohistochemical study of 32 cases.
Histopathology 51(5): 717–719.
May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B,
Gralla O (2007) Validity of the CAPRA score to predict biochemical
recurrence-free survival after radical prostatectomy. Results from
a european multicenter survey of 1,296 patients. J Urol 178(5):
1957–1962, discussion 1962.
Miyamoto H, Hernandez DJ, Epstein JI (2009) A pathological reassessment
of organ-confined, Gleason score 6 prostatic adenocarcinomas
that progress after radical prostatectomy. Hum Pathol 40(12):
1693–1698.
Oxley J, Simpkin A, Goepel J, Varma M, Griffiths D, Grigor K, Mayer N,
Warren A, Deshmukh N, Bhattarai S, Dormer J, Hounsome L,
Adamczyk LA, Metcalfe C, Lane JA, Davis M, Donovan JL, Neal DE,
Hamdy FC, Robinson MC. T. S. G. Protec (2015) Gleason drift in the
NIHR ProtecT study. Histopathology 66(3): 438–446.
Pacelli A, Lopez-Beltran A, Egan AJ, Bostwick DG (1998) Prostatic
adenocarcinoma with glomeruloid features. Hum Pathol 29(5): 543–546.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason
grade grouping: data based on the modified Gleason scoring system. BJU
Int 111(5): 753–760.
Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI (2012)
Do adenocarcinomas of the prostate with Gleason score (GS) r6 have
the potential to metastasize to lymph nodes? Am J Surg Pathol 36(9):
1346–1352.
Rubin MA, Bismar TA, Curtis S, Montie JE (2004) Prostate needle biopsy
reporting: how are the surgical members of the Society of Urologic
Oncology using pathology reports to guide treatment of prostate cancer
patients? Am J Surg Pathol 28(7): 946–952.
Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T
(2011) Overall and worst gleason scores are equally good predictors of
prostate cancer progression. BMC Urol 11: 21.
van der Kwast T (2014) Re: architectural heterogeneity and cribriform pattern
predict adverse clinical outcome for Gleason grade 4 prostatic
adenocarcinoma. Eur Urol 66(1): 174.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
BRITISH JOURNAL OF CANCER Validation of new prostate cancer grading
6 www.bjcancer.com |DOI:10.1038/bjc.2016.86
